Stockscreener 앱 받기
8.22
6.34%
0.49
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem Inc. Earnings Call: Positive Outlook with Key Achievements - MSN
Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - MarketScreener
Breakout Traders Target Verastem Inc. on Recovery SetupWeekly Market Outlook & Precise Swing Trade Entry Alerts - metal.it
Verastem’s VS-7375 shows efficacy in lung cancer - MSN
Verastem shares rise 8.48% premarket after partner's trial data for GFH375 in lung cancer. - AInvest
Verastem stock rises as BTIG reiterates Buy rating on improved cancer drug data - Investing.com Australia
Verastem Soars 16.58% on Positive NSCLC Trial Data - AInvest
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - BioSpace
Verastem Unveils Promising VS-7375 Study Results - MSN
Verastem stock soars after KRAS inhibitor shows strong lung cancer results By Investing.com - Investing.com South Africa
Verastem stock soars after KRAS inhibitor shows strong lung cancer results - Investing.com India
Verastem Oncology Announces Late-Breaking Abstract from Partner - GuruFocus
Verastem Oncology Announces Positive Efficacy Data for Partner GenFleet Therapeutics' KRAS G12D Inhibitor VS-7375 in Advanced Non-Small Cell Lung Cancer. - AInvest
Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Verastem Inc. stock double in the next yearReturn-Focused Stock Plans - thegnnews.com
Will Verastem’s Stock Keep Rising? - StocksToTrade
Verastem (VSTM.O) Surges 19.9% on KDJ Golden Cross and Mysterious Order Flow - AInvest
Verastem Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Verastem Seeks to Raise $300M through Mixed Securities Shelf - AInvest
Verastem's New Ovarian Cancer Drug Sees Strong Sales, Analysts Predict Significant Upside - AInvest
Verastem (VSTM.O) Surges 19.9%: What’s Behind the Sharp Intraday Move? - AInvest
Verastem's Q2 Earnings Exceed Expectations on Strong Ovarian Cancer Drug Sales - AInvest
Using Python tools to backtest Verastem Inc. strategiesAI Trend Detection for Entry Timing - Newser
What makes Verastem Inc. stock price move sharplyMassive ROI Stock Selections - thegnnews.com
Verastem's (VSTM) Breakthrough in KRAS-Driven Cancers and Commercialization Momentum - AInvest
Transcript : Verastem, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Verastem stock climbs on Q2 beat (VSTM:NASDAQ) - Seeking Alpha
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer? - TipRanks
RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk - MarketScreener
Verastem Inc files for mixed shelf offering of up to $300 millionSEC filing - MarketScreener
Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval - Investing.com
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating - TipRanks
Verastem: Q2 Earnings Snapshot - Connecticut Post
Verastem Q2 2025 Earnings Call Transcript - MarketBeat
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive ... By GuruFocus - Investing.com Canada
Verastem Oncology’s Q2 2025 Financial and Business Highlights - TipRanks
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive Positive Momentum - GuruFocus
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem 2025 Q2 Earnings Deepened Losses Amid Product Launch - AInvest
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Custom strategy builders for tracking Verastem Inc.Free Short Term Buy List With Stop Protection - Newser
Verastem Oncology Gambles On Cancer Drug Launch Despite Deepening Losses - Finimize
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Verastem's Q2 2025 Earnings and Pipeline Progress: A Deep Dive into R&D Momentum and Long-Term Value Creation - AInvest
Biopharma firm Verastem Oncology Q2 net loss widens - MarketScreener
Verastem reports Q2 EPS (39c) vs. (31c) last year - TipRanks
Verastem CEO Paterson sells $7,738 in shares By Investing.com - Investing.com South Africa
Verastem CEO Paterson sells $7,738 in shares - Investing.com
Will Verastem Inc. continue its uptrendIntelligent Trade Forecast With AI Analytics - Newser
Intrinsic Value of Verastem Inc. Stock: Is It Undervalued or OvervaluedTechnical Trend Forecast for Investors - Newser
Best data tools to analyze Verastem Inc. stockTrading Watchlist with Real Time Filters - Newser
Visual trend scoring systems applied to Verastem Inc.Free Pattern Alert With ROI Driven Strategy - Newser
Leading vs lagging indicators on Verastem Inc. performanceFree News Based Entry Opportunity Alerts - Newser
0.41%
0.88%
자본화:
|
볼륨(24시간):